These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia. Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491 [TBL] [Abstract][Full Text] [Related]
24. Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales. Nordmann P; Bouvier M; Poirel L; Sadek M J Antimicrob Chemother; 2022 Nov; 77(12):3456-3461. PubMed ID: 36226737 [TBL] [Abstract][Full Text] [Related]
25. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004 [TBL] [Abstract][Full Text] [Related]
27. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
28. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria. Ong'uti S; Czech M; Robilotti E; Holubar M Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098 [TBL] [Abstract][Full Text] [Related]
29. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050 [TBL] [Abstract][Full Text] [Related]
30. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397 [TBL] [Abstract][Full Text] [Related]
31. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related]
32. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018. Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792 [TBL] [Abstract][Full Text] [Related]
33. Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability. Stracquadanio S; Bonomo C; Marino A; Bongiorno D; Privitera GF; Bivona DA; Mirabile A; Bonacci PG; Stefani S Microbiol Spectr; 2022 Oct; 10(5):e0234722. PubMed ID: 36173300 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019). Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312 [TBL] [Abstract][Full Text] [Related]
35. Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3. Malik S; Kaminski M; Landman D; Quale J Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868330 [TBL] [Abstract][Full Text] [Related]
36. [Discovery of a New Siderophore Cephalosporin, Cefiderocol]. Yamano Y Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Marner M; Kolberg L; Horst J; Böhringer N; Hübner J; Kresna IDM; Liu Y; Mettal U; Wang L; Meyer-Bühn M; Mihajlovic S; Kappler M; Schäberle TF; von Both U Microbiol Spectr; 2023 Feb; 11(1):e0443722. PubMed ID: 36692293 [TBL] [Abstract][Full Text] [Related]
39. Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii. Liu X; Lei T; Yang Y; Zhang L; Liu H; Leptihn S; Yu Y; Hua X Antimicrob Agents Chemother; 2022 Dec; 66(12):e0082822. PubMed ID: 36377939 [TBL] [Abstract][Full Text] [Related]
40. MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. Raro OHF; Bouvier M; Kerbol A; Poirel L; Nordmann P Int J Antimicrob Agents; 2024 Aug; 64(2):107206. PubMed ID: 38754526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]